Boxes for the GLP-1 medications Wegovy (semaglutide) and Zepbound (tirzepatide) pictured in California, May 8, 2025
Clinical efficacy data from the SURMOUNT and other branded-drug trials applies only to the FDA-approved products studied and does not apply to any compounded formulation
Before starting Glipiq 0.25mg/0.5mg Injection, inform your doctor about any medical conditions you have, particularly a history of pancreatitis, eye problems caused by diabetes (diabetic retinopathy), thyroid cancer, or severe gastrointestinal problems
Importantly, do not reduce or stop insulin without medical advice when starting or adjusting Rybelsus, as this could increase the risk of diabetic ketoacidosis (DKA), as highlighted in MHRA safety guidance
Too little water creates a highly concentrated solution that is prone to aggregation